Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V. Pipe SW, et al. Among authors: kiialainen a. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16. Lancet Haematol. 2019. PMID: 31003963 Clinical Trial.
Low immunogenicity of emicizumab in persons with haemophilia A.
Schmitt C, Emrich T, Chebon S, Fernandez E, Petry C, Yoneyama K, Kiialainen A, Howard M, Niggli M, Paz-Priel I, Chang T. Schmitt C, et al. Among authors: kiialainen a. Haemophilia. 2021 Nov;27(6):984-992. doi: 10.1111/hae.14398. Epub 2021 Sep 4. Haemophilia. 2021. PMID: 34480814 Free PMC article.
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
Nishimura JI, Usuki K, Ramos J, Ichikawa S, Buri M, Kiialainen A, Sostelly A, Peffault de Latour R, Paz-Priel I, Röth A. Nishimura JI, et al. Among authors: kiialainen a. Br J Haematol. 2022 Aug;198(3):e46-e50. doi: 10.1111/bjh.18274. Epub 2022 May 24. Br J Haematol. 2022. PMID: 35608260 No abstract available.
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K, Schmitt C, Portron A, Kiialainen A, Kotani N, Jaminion F, Retout S, Adamkewicz JI. Yoneyama K, et al. Among authors: kiialainen a. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):775-790. doi: 10.1080/17512433.2023.2243213. Epub 2023 Aug 21. Expert Rev Clin Pharmacol. 2023. PMID: 37529848 Review.
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C. Kiialainen A, et al. Res Pract Thromb Haemost. 2023 Dec 29;8(1):102306. doi: 10.1016/j.rpth.2023.102306. eCollection 2024 Jan. Res Pract Thromb Haemost. 2023. PMID: 38282901 Free PMC article.
Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
Jiménez-Yuste V, Peyvandi F, Klamroth R, Castaman G, Shanmukhaiah C, Rangarajan S, García Chavez J, Martinez R, Kenet G, Alzahrani H, Robson S, Schmitt C, Kiialainen A, Meier O, Ozelo M. Jiménez-Yuste V, et al. Among authors: kiialainen a. Res Pract Thromb Haemost. 2022 Nov 14;6(8):e12837. doi: 10.1002/rth2.12837. eCollection 2022 Nov. Res Pract Thromb Haemost. 2022. PMID: 36397934 Free PMC article.
33 results